<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04331314</url>
  </required_header>
  <id_info>
    <org_study_id>27-224 ex 14/15</org_study_id>
    <nct_id>NCT04331314</nct_id>
  </id_info>
  <brief_title>Biphasic Calcium Phosphate vs. Hydroxyapatite in Sinus Floor Elevation</brief_title>
  <official_title>Sinus Augmentation Using Symbios Versus Algipore as Bone Graft Material - A Randomized Controlled Clinical Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dentsply Sirona Implants</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Twenty patients scheduled for lateral-window sinus floor Elevation (SFE) are randomized into
      two groups: use of SYMBIOS® Biphasic Bone Graft Material (Group 1) or of Algipore® Bone
      Substitution Material (Group 2).

      Biopsies are taken 3 months after SFE and during implant surgery after 6 months. One ground
      section per biopsy (n=40) is stained, scanned, and histomorphometrically analyzed for new
      bone, old bone, soft tissue, graft, bone infiltration of graft, bone-to-graft contact, and
      penetration depth.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2015</start_date>
  <completion_date type="Actual">October 28, 2019</completion_date>
  <primary_completion_date type="Actual">March 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Twenty patients scheduled for lateral-window sinus floor Elevation SFE will be randomized to an HA and a β-TCP/HA Group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Implant stability</measure>
    <time_frame>12 months after sinus augmentation</time_frame>
    <description>measured with Periotest®</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival rate of the implants</measure>
    <time_frame>24 months after sinus augmentation</time_frame>
    <description>Rate of loss of implants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probing on depth</measure>
    <time_frame>24 months after sinus augmentation</time_frame>
    <description>The measurement of probing depth will be performed with a CPITN probe with 0.5mm ball head</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding on probing</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crestal bone level after implant</measure>
    <time_frame>12 months after implant placement</time_frame>
    <description>measured by means of single tooth x-rays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>6 months after sinus augmentation</time_frame>
    <description>Frequency of complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Newly formed bone area in mm²</measure>
    <time_frame>3 months after sinus augmentation</time_frame>
    <description>measured through histomorphological analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Newly formed bone area in mm²</measure>
    <time_frame>6 months after sinus augmentation</time_frame>
    <description>measured through histomorphological analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Old bone area in mm²</measure>
    <time_frame>3 months after sinus augmentation</time_frame>
    <description>measured through histomorphological analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Old bone area in mm²</measure>
    <time_frame>6 months after sinus augmentation</time_frame>
    <description>measured through histomorphological analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue area in mm²</measure>
    <time_frame>3 months after sinus augmentation</time_frame>
    <description>measured through histomorphological analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue area in mm²</measure>
    <time_frame>6 months after sinus augmentation</time_frame>
    <description>measured through histomorphological analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone substitute area in mm²</measure>
    <time_frame>3 months after sinus augmentation</time_frame>
    <description>measured through histomorphological analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone substitute area in mm²</measure>
    <time_frame>6 months after sinus augmentation</time_frame>
    <description>measured through histomorphological analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New bone infiltration area in bone substitute in mm²</measure>
    <time_frame>3 months after sinus augmentation</time_frame>
    <description>measured through histomorphological analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New bone infiltration area in bone substitute in mm²</measure>
    <time_frame>6 months after sinus augmentation</time_frame>
    <description>measured through histomorphological analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new bone to bone substitute contact in mm</measure>
    <time_frame>6 months after sinus augmentation</time_frame>
    <description>measured through histomorphological analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penetration depth in mm</measure>
    <time_frame>3 months after sinus augmentation</time_frame>
    <description>measured through histomorphological analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penetration depth in mm</measure>
    <time_frame>6 months after sinus augmentation</time_frame>
    <description>measured through histomorphological analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Bone Substitutes</condition>
  <condition>Calcium Phosphates</condition>
  <condition>Hydroxyapatite</condition>
  <condition>Rhodophyta</condition>
  <condition>Sinus Floor Augmentation</condition>
  <arm_group>
    <arm_group_label>SYMBIOS®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sinus augmentation with SYMBIOS® Biphasic Bone Graft Material</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Algipore®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sinus augmentation with Algipore® Bone Substitution Material</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Use of Symbios Bone Graft Material</intervention_name>
    <description>Patients will receive Symbios Bone Graft Material according to randomization Group.</description>
    <arm_group_label>SYMBIOS®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Algipore Bone Substitution Material</intervention_name>
    <description>Patients will receive Algipore Bone Substitution Material according to randomization Group.</description>
    <arm_group_label>Algipore®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Capability of giving an informed consent

          2. Good health as defined by the subject's medical history

          3. Patients age 20-75 years

          4. Fully edentulous or partially edentulous patients with unilateral or bilateral missing
             teeth in the maxillary premolar or molar areas with severe alveolar atrophy and a
             residual alveolar ridge height of maximal 5 mm requiring a two-staged sinus floor
             elevation and implant placement.

        Exclusion Criteria:

          1. Patients without detailed baseline medical data

          2. Patients with medical history of local inflammations in the posterior maxilla

          3. Skeletal immaturity

          4. Patients with osteoporosis in their medical history

          5. Patients with severe illnesses, malignant diseases, radiotherapy or chemotherapy in
             their medical history

          6. Patients with pathological fractures

          7. Patients treated with bisphosphonates

          8. Uncontrolled diabetes mellitus

          9. Uncontrolled periodontal diseases

         10. Smoking

         11. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walther Wegscheider, Prof. DDr.</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Department</affiliation>
  </overall_official>
  <reference>
    <citation>Cordaro L, Bosshardt DD, Palattella P, Rao W, Serino G, Chiapasco M. Maxillary sinus grafting with Bio-Oss or Straumann Bone Ceramic: histomorphometric results from a randomized controlled multicenter clinical trial. Clin Oral Implants Res. 2008 Aug;19(8):796-803. doi: 10.1111/j.1600-0501.2008.01565.x.</citation>
    <PMID>18705811</PMID>
  </reference>
  <reference>
    <citation>Chiapasco M, Casentini P, Zaniboni M. Bone augmentation procedures in implant dentistry. Int J Oral Maxillofac Implants. 2009;24 Suppl:237-59. Review.</citation>
    <PMID>19885448</PMID>
  </reference>
  <reference>
    <citation>Schopper C, Moser D, Sabbas A, Lagogiannis G, Spassova E, König F, Donath K, Ewers R. The fluorohydroxyapatite (FHA) FRIOS Algipore is a suitable biomaterial for the reconstruction of severely atrophic human maxillae. Clin Oral Implants Res. 2003 Dec;14(6):743-9.</citation>
    <PMID>15015951</PMID>
  </reference>
  <reference>
    <citation>Ewers R. Maxilla sinus grafting with marine algae derived bone forming material: a clinical report of long-term results. J Oral Maxillofac Surg. 2005 Dec;63(12):1712-23.</citation>
    <PMID>16297691</PMID>
  </reference>
  <reference>
    <citation>Scarano A, Degidi M, Perrotti V, Piattelli A, Iezzi G. Sinus augmentation with phycogene hydroxyapatite: histological and histomorphometrical results after 6 months in humans. A case series. Oral Maxillofac Surg. 2012 Mar;16(1):41-5. doi: 10.1007/s10006-011-0296-3. Epub 2011 Sep 24.</citation>
    <PMID>21947545</PMID>
  </reference>
  <reference>
    <citation>Kühl S, Payer M, Kirmeier R, Wildburger A, Acham S, Jakse N. The influence of particulated autogenous bone on the early volume stability of maxillary sinus grafts with biphasic calcium phosphate: a randomized clinical trial. Clin Implant Dent Relat Res. 2015 Feb;17(1):173-8. doi: 10.1111/cid.12086. Epub 2013 May 28.</citation>
    <PMID>23714235</PMID>
  </reference>
  <reference>
    <citation>Raghoebar GM, Onclin P, Boven GC, Vissink A, Meijer HJA. Long-term effectiveness of maxillary sinus floor augmentation: A systematic review and meta-analysis. J Clin Periodontol. 2019 Jun;46 Suppl 21:307-318. doi: 10.1111/jcpe.13055.</citation>
    <PMID>30624789</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium Metabolism Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

